GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDS Biotechnology Corp (STU:EU6) » Definitions » EV-to-FCF

PDS Biotechnology (STU:EU6) EV-to-FCF : -3.20 (As of May. 06, 2024)


View and export this data going back to 2016. Start your Free Trial

What is PDS Biotechnology EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, PDS Biotechnology's Enterprise Value is €100.10 Mil. PDS Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-31.24 Mil. Therefore, PDS Biotechnology's EV-to-FCF for today is -3.20.

The historical rank and industry rank for PDS Biotechnology's EV-to-FCF or its related term are showing as below:

STU:EU6' s EV-to-FCF Range Over the Past 10 Years
Min: -45.38   Med: 0   Max: 0
Current: -3.19

STU:EU6's EV-to-FCF is ranked worse than
100% of 382 companies
in the Biotechnology industry
Industry Median: 5.84 vs STU:EU6: -3.19

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-06), PDS Biotechnology's stock price is €3.518. PDS Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.290. Therefore, PDS Biotechnology's PE Ratio for today is At Loss.


PDS Biotechnology EV-to-FCF Historical Data

The historical data trend for PDS Biotechnology's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDS Biotechnology EV-to-FCF Chart

PDS Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.10 -1.48 -13.27 -13.53 -3.92

PDS Biotechnology Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.53 -4.53 -3.76 -3.85 -3.92

Competitive Comparison of PDS Biotechnology's EV-to-FCF

For the Biotechnology subindustry, PDS Biotechnology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PDS Biotechnology's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PDS Biotechnology's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where PDS Biotechnology's EV-to-FCF falls into.



PDS Biotechnology EV-to-FCF Calculation

PDS Biotechnology's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=100.102/-31.241
=-3.20

PDS Biotechnology's current Enterprise Value is €100.10 Mil.
PDS Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-31.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PDS Biotechnology  (STU:EU6) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

PDS Biotechnology's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.518/-1.290
=At Loss

PDS Biotechnology's share price for today is €3.518.
PDS Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.290.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


PDS Biotechnology EV-to-FCF Related Terms

Thank you for viewing the detailed overview of PDS Biotechnology's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


PDS Biotechnology (STU:EU6) Business Description

Traded in Other Exchanges
Address
25B Vreeland Road, Suite 300, Florham Park, NJ, USA, 07932
PDS Biotechnology Corp operates as a clinical-stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

PDS Biotechnology (STU:EU6) Headlines

No Headlines